(CDAX, Technology, BSL GR)



Buy EUR 18.00		Value Indicators: DCF: FCF-Value Potential 26e:		Warburg Risk Score: Balance Sheet Score: Market Liquidity Score:	<b>2.3</b> 3.5 1.0	<b>Description:</b> B2B digital cameras for applisuch as factory, medical, trafretail.	
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2024e
		Market cap:	184.4	Freefloat	41.00 %	Beta:	1.2
Price	EUR 6.00	No. of shares (m):	30.7	Norbert Basler	53.00 %	Price / Book:	1.4 x
Upside	200.0 %	EV:	236.6	Dr. Ley (CEO)	4.00 %	Equity Ratio:	54 %
Cherne		Freefloat MC:	75.6	Treasury shares	2.00 %	Net Fin. Debt / EBITDA:	5.8 x
		Ø Trad. Vol. (30d):	181.85 th	Union Investment	5.00 %	Net Debt / EBITDA:	6.0 x

## Market environment expected to remain challenging next year

Stated Figure	es Q3/2	024:							Comment on Figures:
FY End: 31.12. in EUR m	Q3 24	Q3 24e	Q3 23	уоу	9M 24	9M 24e	9M 23	уоу	<ul> <li>Sales down 12% qoq as demand weakens in Europe</li> <li>Top line below the quarterly EBT break-even point of EUR 50m</li> </ul>
Sales	43.7	43.7	41.5	5 %	136.7	136.8	157.5	-13 %	<ul> <li>As a result, EBT, which was slightly positive in Q2, turned negative ag</li> </ul>
EBT	-2.6	-2.6	-16.3	n.a.	-4.9	-4.9	-16.1	n.a.	
Margin	-6.1 %	-5.9 %	-39.3 %		-3.6 %	-3.6 %	-10.2 %		
EPS	-0.11	-0.10	-0.52	n.a.	-0.22	-0.20	-0.58	n.a.	

Basler has published its final Q3 report, which was in line with the preliminary figures, and confirmed the recently reduced guidance (sales EUR 178-184m, EBT EUR -8 to -12m). Quarterly revenue of EUR 43.7m increased by 5.4% compared to the weak Q3 23, but declined by 11.7% compared to Q2 24 as demand from the consumer electronics and e-mobility industries remained at a low level and the European business, which was robust in H1, continued to decline.

As a result, sales fell below the quarterly EBT break-even point of roughly EUR 50m, and EBT of EUR -2.6m turned negative again after the profitable Q2. Despite the weak operating performance, FCF of EUR 3.6m in Q3 was strong compared to last year (EUR -1.5m) and last quarter (EUR 1.3m), driven by working-capital improvements. Excluding acquisition costs, FCF was even stronger at EUR 6.5m.

Against this background, the company has decided to implement additional cost-cutting measures with the aim of further reducing the EBT breakeven point from the current level of EUR 200m to EUR 180m. The restructuring is scheduled for the fourth quarter and should result in one-offs of approx. EUR 5.5m, which are included in the adjusted guidance. Thus, even without notable growth next year, the company should be able to break even in 2025. To return to the 12% EBT margin that the company has achieved in the past, Basler would require a sales volume of approx. EUR 240m. The company also confirmed its 2027 target of EUR 300m in sales and a 12% EBT margin, with the caveat that demand will need to pick up over the course of 2025 in order to achieve these goals.


We had already significantly lowered our forecasts with the preliminary figures and maintain our estimates. We currently do not expect Basler to return to an EBT margin of 12% before 2028. The slower recovery anticipated in our model reflects the limited visibility and a conservative approach to the timing of a recovery. However, we are still convinced that the markets will recover and that Basler will maintain a strong market position. Therefore, when demand picks up, there is notable upside to our current estimates and the resulting target price.

For the time being, we maintain our cautious outlook, our target price of EUR 18 and our Buy recommendation for Basler.

13 12 M. Mill		FY End: 31.12. in EUR m	CAGR (23-26e)	2020	2021	2022	2023	2024e	2025e	2026e
11- M & My commentation	ann	Sales	3.2 %	170.5	214.7	272.2	203.1	181.4	191.6	223.0
10 - Al-Armyton and a strange		Change Sales yoy		5.2 %	26.0 %	26.8 %	-25.4 %	-10.7 %	5.6 %	16.4 %
	my .	Gross profit margin		52.0 %	52.4 %	48.4 %	42.2 %	49.8 %	50.0 %	50.3 %
9-1	VIA	EBITDA	188.8 %	34.6	44.5	45.8	1.7	8.7	27.7	40.9
8 -		Margin		20.3 %	20.7 %	16.8 %	0.8 %	4.8 %	14.5 %	18.3 %
7 -		EBIT	-	20.1	28.4	28.9	-21.9	-8.5	9.3	21.2
		Margin		11.8 %	13.2 %	10.6 %	-10.8 %	-4.7 %	4.9 %	9.5 %
6 -	7	EBT		20.4	28.0	28.3	-20.2	-9.7	7.8	19.7
5 01/24 03/24 05/24 07/24	09/24 11/24	Margin		12.0 %	13.0 %	10.4 %	-9.9 %	-5.3 %	4.1 %	8.8 %
	09/24 11/24	Net income	-	15.1	20.8	21.4	-13.8	-7.0	5.6	14.1
Basler — CDAX (normalised)		EPS	-	0.50	0.69	0.71	-0.45	-0.23	0.18	0.46
Rel. Performance vs CDAX:		DPS	-	0.19	0.21	0.14	0.00	0.00	0.00	0.10
		Dividend Yield		1.1 %	0.5 %	0.4 %	n.a.	n.a.	n.a.	1.7 %
1 month:	-36.3 %	FCFPS		0.46	0.32	-0.59	-0.31	0.41	0.35	0.28
6 months:	-49.2 %	FCF / Market cap		2.6 %	0.8 %	-1.8 %	-1.6 %	6.8 %	5.8 %	4.7 %
Year to date:	-58.9 %	EV / Sales		3.2 x	5.5 x	3.7 x	3.1 x	1.3 x	1.2 x	1.0 x
Trailing 12 months:	-54.0 %	EV / EBITDA		15.6 x	26.5 x	22.3 x	370.5 x	27.1 x	8.2 x	5.4 x
5		EV / EBIT		26.9 x	41.7 x	35.2 x	n.a.	n.a.	24.5 x	10.4 x
Company events:		P/E		36.1 x	57.2 x	45.6 x	n.a.	n.a.	33.3 x	13.0 x
		FCF Potential Yield		4.6 %	2.5 %	3.1 %	0.5 %	2.4 %	8.4 %	12.7 %
		ROE		13.9 %	17.0 %	15.8 %	-9.8 %	-5.1 %	3.9 %	8.7 %
		ROCE (NOPAT)		12.8 %	17.3 %	13.5 %	n.a.	n.a.	3.5 %	7.5 %
		Guidance: S	Sales EUR 17	8-184m, EB1	EUR -8 to -	12m				

Analyst **Robert-Jan van der Horst** rvanderhorst@warburg-research.com +49 40 309537-290






## **Company Background**

- Basler is a full-line supplier of camera solutions for production, medical applications, traffic control or retail.
- Basler focuses on the mainstream and entry-level market segments.
- Customers are mainly OEMs. The customer base is well diversified and no single customer accounts for more than 10% of revenue. Almost 80% of revenues are direct sales.

## **Competitive Quality**

- In terms of units Basler is the world's largest developer and manufacturer of digital cameras in a fragmented, but consolidating, market for digital cameras for B2B-applications.
- High level of vision technology expertise: Basler has one of the largest developer pools in the sector and differentiates itself with camera software competence, which accounts for more than 50% of the value creation.
- State-of-the-art product portfolio: Basler is among the first movers in digital cameras based on GigE Vision and the USB3 Vision standard. It is also an early adopter of new sensor technology.
- High service and consulting quality through direct sales and Basler's network of specialised distributors.
- Basler is present in the most important markets for vision technology in South East Asia, Europe and the US.





DCF model														
	Detaile	d forecas	st period				Г	ransition	al period					Term. Value
Figures in EUR m	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	
Sales	181.4	191.6	223.0	256.3	293.8	336.1	383.6	437.0	496.8	563.6	638.1	720.9	814.6	
Sales change	-10.7 %	5.6 %	16.4 %	14.9 %	14.6 %	14.4 %	14.2 %	13.9 %	13.7 %	13.4 %	13.2 %	13.0 %	13.0 %	2.5 %
EBIT	-8.5	9.3	21.2	26.9	33.8	40.3	46.0	52.4	59.6	67.6	79.8	90.1	101.8	
EBIT-margin	-4.7 %	4.9 %	9.5 %	10.5 %	11.5 %	12.0 %	12.0 %	12.0 %	12.0 %	12.0 %	12.5 %	12.5 %	12.5 %	
Tax rate (EBT)	28.0 %	28.0 %	28.5 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	
NOPAT	-6.1	6.7	15.1	19.4	24.3	29.0	33.1	37.8	42.9	48.7	57.4	64.9	73.3	
Depreciation	17.2	18.4	19.7	20.5	22.0	23.5	24.9	28.4	32.3	36.6	41.5	46.9	52.9	
in % of Sales	9.5 %	9.6 %	8.8 %	8.0 %	7.5 %	7.0 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	
Changes in provisions	0.0	0.0	0.0	0.2	0.2	0.3	0.3	0.3	0.4	0.4	0.4	0.5	0.6	
Change in Liquidity from														
- Working Capital	-17.5	-5.0	4.1	5.7	5.9	7.2	8.1	9.1	10.2	11.4	12.7	14.1	15.9	
- Capex	15.2	18.3	20.9	20.5	22.0	23.5	26.1	28.8	32.3	36.6	41.5	46.9	52.9	
Capex in % of Sales	8.4 %	9.6 %	9.4 %	8.0 %	7.5 %	7.0 %	6.8 %	6.6 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	
- Other	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	9.2	11.7	9.8	13.9	18.7	22.1	24.2	28.6	33.1	37.7	45.2	51.3	58.0	72
PV of FCF	9.1	10.7	8.3	10.8	13.3	14.5	14.6	15.9	16.9	17.7	19.6	20.4	21.2	426
share of PVs		4.54 %						26.62	2 %					68.84 %
Model parameter							Valuati	on (m)						
Derivation of WACC:			Derivation	of Beta:			Presen	t values 20	036e	19	93			
							Termin	al Value		42	26			
Debt ratio	8.00 %		Financial S	Strength		1.20	Financi	al liabilitie	s	ε	39			
Cost of debt (after tax)	2.1 %		Liquidity (s	hare)		1.20		n liabilities	i		1			
Market return	8.25 %		Cyclicality			1.40	Hybrid	•			0			
Risk free rate	2.75 %		Transpare	псу		1.00		y interest			0			
			Others			1.10		val. of inv	estments		0			
							Liquidit	,			29	No. of sha	. ,	30.7
WACC	8.67 %		Beta			1.18	Equity	Value		55	58	Value per	share (E	UR) 18.15

#### Sensitivity Value per Share (EUR)

		Terminal	Growth								Delta EBIT	-margin					
Beta	WACC	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	3.00 %	3.25 %	Beta	WACC	-1.5 pp	<b>-1</b> .0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.38	9.7 %	13.56	13.87	14.21	14.57	14.95	15.37	15.82	1.38	9.7 %	12.23	13.01	13.79	14.57	15.35	16.13	16.91
1.28	9.2 %	14.99	15.37	15.77	16.21	16.69	17.20	17.75	1.28	9.2 %	13.66	14.51	15.36	16.21	17.06	17.92	18.77
1.23	8.9 %	15.78	16.20	16.65	17.14	17.66	18.23	18.85	1.23	8.9 %	14.46	15.36	16.25	17.14	18.03	18.92	19.81
1.18	8.7 %	16.64	17.11	17.60	18.15	18.73	19.37	20.06	1.18	8.7 %	15.34	16.28	17.21	18.15	19.08	20.01	20.95
1.13	8.4 %	17.57	18.08	18.64	19.24	19.90	20.61	21.40	1.13	8.4 %	16.30	17.28	18.26	19.24	20.22	21.21	22.19
1.08	8.2 %	18.58	19.15	19.77	20.44	21.18	21.99	22.88	1.08	8.2 %	17.34	18.38	19.41	20.44	21.48	22.51	23.54
0.98	7.7 %	20.87	21.58	22.36	23.21	24.15	25.20	26.36	0.98	7.7 %	19.76	20.91	22.06	23.21	24.37	25.52	26.67

• Financial liabilities are also related to the lease of the company building.

• The beta takes into consideration Basler's strong track record, the high equity ratio and the cyclicality

• The structural growth of the vision technology market forms the basis of Basler's revenue increases.

- Cash inflow from treasury share sales are accounted for in the "others" line



### **Free Cash Flow Value Potential**

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

in EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Net Income before minorities	15.1	20.8	21.4	-13.8	-7.0	5.6	14.1
+ Depreciation + Amortisation	14.5	16.2	16.8	23.6	17.2	18.4	19.7
- Net Interest Income	0.4	-0.4	-0.6	1.7	-1.2	-1.5	-1.5
- Maintenance Capex	4.4	7.5	7.5	5.1	5.7	6.3	7.1
+ Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Free Cash Flow Potential	24.9	29.8	31.3	3.0	5.8	19.2	28.2
FCF Potential Yield (on market EV)	4.6 %	2.5 %	3.1 %	0.5 %	2.4 %	8.4 %	12.7 %
WACC	8.67 %	8.67 %	8.67 %	8.67 %	8.67 %	8.67 %	8.67 %
= Enterprise Value (EV)	540.1	1,181.7	1,019.3	629.1	236.6	227.9	221.2
= Fair Enterprise Value	287.3	343.9	360.7	34.6	66.5	221.6	325.1
- Net Debt (Cash)	57.2	57.2	57.2	57.2	50.8	42.2	35.4
- Pension Liabilities	1.3	1.3	1.3	1.3	1.3	1.3	1.3
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<ul> <li>Market value of minorities</li> </ul>	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Market value of investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Fair Market Capitalisation	228.8	285.4	302.2	n.a.	14.4	178.0	288.3
Number of shares, average	30.0	29.9	29.9	30.3	30.7	30.7	30.7
= Fair value per share (EUR)	7.62	9.54	10.12	n.a.	0.47	5.79	9.38
premium (-) / discount (+) in %					-92.2 %	-3.5 %	56.3 %
Sensitivity Fair value per Share (EUR)							
11.67 %	5.04	6.41	6.82	n.a.	n.a.	3.94	6.66
10.67 %	5.69	7.19	7.63	n.a.	0.06	4.44	7.40
9.67 %	6.48	8.13	8.62	n.a.	0.24	5.05	8.29
WACC 8.67 %	7.62	9.54	10.12	n.a.	0.47	5.79	9.38
7.67 %	8.66	10.74	11.36	n.a.	0.75	6.73	10.76
6.67 %	10.25	12.64	13.35	n.a.	1.12	7.95	12.55
5.67 %	12.39	15.20	16.04	n.a.	1.61	9.61	14.98

Assumptions on the beta and the wacc are consistent with indicators used in our DCF model

• The capex requirements for machinery and plant are low.



Valuation							
	2020	2021	2022	2023	2024e	2025e	2026e
Price / Book	4.7 x	9.2 x	6.8 x	4.1 x	1.4 x	1.2 x	1.1 x
Book value per share ex intangibles	1.62	2.09	1.57	1.60	1.09	1.00	1.14
EV / Sales	3.2 x	5.5 x	3.7 x	3.1 x	1.3 x	1.2 x	1.0 x
EV / EBITDA	15.6 x	26.5 x	22.3 x	370.5 x	27.1 x	8.2 x	5.4 x
EV / EBIT	26.9 x	41.7 x	35.2 x	n.a.	n.a.	24.5 x	10.4 x
EV / EBIT adj.*	26.9 x	41.7 x	35.2 x	n.a.	n.a.	24.5 x	10.4 x
P / FCF	39.2 x	122.9 x	n.a.	n.a.	14.7 x	17.3 x	21.1 x
P/E	36.1 x	57.2 x	45.6 x	n.a.	n.a.	33.3 x	13.0 x
P / E adj.*	36.8 x	57.2 x	45.6 x	n.a.	n.a.	33.3 x	13.0 x
Dividend Yield	1.1 %	0.5 %	0.4 %	n.a.	n.a.	n.a.	1.7 %
FCF Potential Yield (on market EV)	4.6 %	2.5 %	3.1 %	0.5 %	2.4 %	8.4 %	12.7 %
*Adjustments made for: -							




## Consolidated profit and loss

In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Sales	170.5	214.7	272.2	203.1	181.4	191.6	223.0
Change Sales yoy	5.2 %	26.0 %	26.8 %	-25.4 %	-10.7 %	5.6 %	16.4 %
COGS	81.7	102.2	140.4	117.4	91.1	95.8	110.8
Gross profit	88.7	112.5	131.8	85.7	90.3	95.8	112.2
Gross margin	52.0 %	52.4 %	48.4 %	42.2 %	49.8 %	50.0 %	50.3 %
Research and development	21.7	29.9	31.4	37.2	29.1	27.2	29.1
Sales and marketing	30.6	34.9	47.9	42.9	40.3	38.1	39.8
Administration expenses	17.4	20.4	26.7	29.9	23.8	21.9	22.9
Other operating expenses	0.2	0.3	0.5	0.4	6.8	0.5	0.5
Other operating income	1.1	1.3	3.6	2.7	1.2	1.2	1.3
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	34.6	44.5	45.8	1.7	8.7	27.7	40.9
Margin	20.3 %	20.7 %	16.8 %	0.8 %	4.8 %	14.5 %	18.3 %
Depreciation of fixed assets	6.3	6.3	5.5	7.3	7.2	7.8	8.5
EBITA	28.3	38.2	40.2	-5.6	1.5	19.9	32.4
Amortisation of intangible assets	8.2	9.8	11.3	16.3	10.0	10.6	11.2
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	20.1	28.4	28.9	-21.9	-8.5	9.3	21.2
Margin	11.8 %	13.2 %	10.6 %	-10.8 %	-4.7 %	4.9 %	9.5 %
EBIT adj.	20.1	28.4	28.9	-9.7	-8.5	9.3	21.2
Interest income	1.1	0.2	0.3	3.3	0.4	0.4	0.4
Interest expenses	0.8	0.6	1.0	1.8	1.9	1.9	1.9
Other financial income (loss)	0.0	0.0	0.2	0.2	0.3	0.0	0.0
EBT	20.4	28.0	28.3	-20.2	-9.7	7.8	19.7
Margin	12.0 %	13.0 %	10.4 %	-9.9 %	-5.3 %	4.1 %	8.8 %
Total taxes	5.3	7.2	7.0	-6.4	-2.7	2.2	5.6
Net income from continuing operations	15.1	20.8	21.4	-13.8	-7.0	5.6	14.1
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	15.1	20.8	21.4	-13.8	-7.0	5.6	14.1
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	15.1	20.8	21.4	-13.8	-7.0	5.6	14.1
Margin	8.9 %	9.7 %	7.8 %	-6.8 %	-3.8 %	2.9 %	6.3 %
Number of shares, average	30.0	29.9	29.9	30.3	30.7	30.7	30.7
EPS	0.50	0.69	0.71	-0.45	-0.23	0.18	0.46
EPS adj.	0.49	0.69	0.71	-0.45	-0.23	0.18	0.46
*Adjustments made for:							


Guidance: Sales EUR 178-184m, EBT EUR -8 to -12m

#### **Financial Ratios**

	2020	2021	2022	2023	2024e	2025e	2026e
Total Operating Costs / Sales	40.3 %	39.2 %	37.8 %	53.0 %	54.5 %	45.1 %	40.8 %
Operating Leverage	3.4 x	1.6 x	0.1 x	n.a.	5.7 x	n.a.	7.8 x
EBITDA / Interest expenses	45.0 x	75.4 x	43.8 x	0.9 x	4.6 x	14.6 x	21.5 x
Tax rate (EBT)	26.0 %	25.8 %	24.6 %	31.6 %	28.0 %	28.0 %	28.5 %
Dividend Payout Ratio	38.4 %	29.8 %	19.6 %	0.0 %	0.0 %	0.0 %	21.8 %
Sales per Employee	210,964	248,528	242,173	182,155	161,676	165,458	192,593



#### Performance per Share



COMMENT Publ

Published 08.11.2024

6


#### Consolidated balance .



Consolidated balance sheet							
In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Assets							
Goodwill and other intangible assets	64.8	66.0	94.5	90.1	102.6	118.8	138.0
thereof other intangible assets	3.7	6.5	13.8	13.7	24.3	37.0	51.3
thereof Goodwill	27.5	27.5	46.1	45.8	45.8	45.8	45.8
Property, plant and equipment	29.3	28.7	29.4	36.9	32.4	26.1	19.6
Financial assets	2.2	0.0	1.4	1.8	1.8	1.8	1.8
Other long-term assets	0.0	0.0	3.8	5.5	5.5	5.5	5.5
Fixed assets	96.3	94.7	129.1	134.3	142.3	152.2	164.9
Inventories	20.0	37.1	50.3	44.0	29.3	24.9	29.3
Accounts receivable	19.5	33.3	41.2	27.4	22.4	22.0	24.4
Liquid assets	47.9	54.8	28.7	32.2	38.5	47.2	54.0
Other short-term assets	6.5	7.3	16.2	17.8	17.8	17.8	17.8
Current assets	93.8	132.5	136.4	121.5	108.0	111.9	125.4
Total Assets	190.1	227.3	265.5	255.8	250.3	264.1	290.4
Liabilities and shareholders' equity							
Subscribed capital	10.0	10.0	29.8	30.7	30.7	30.7	30.7
Capital reserve	22.6	26.8	7.2	10.7	10.7	10.7	10.7
Retained earnings	87.1	94.2	107.2	102.5	95.5	101.1	115.2
Other equity components	-4.8	-2.4	-2.8	-4.7	-0.9	7.1	16.6
Shareholders' equity	114.9	128.7	141.5	139.2	136.0	149.6	173.2
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	114.9	128.7	141.5	139.2	136.0	149.6	173.2
Provisions	9.4	16.0	14.6	9.3	9.3	9.3	9.3
thereof provisions for pensions and similar obligations	1.1	1.6	2.0	1.3	1.3	1.3	1.3
Financial liabilities (total)	45.1	54.4	79.1	89.4	89.4	89.4	89.4
Short-term financial liabilities	4.1	4.1	4.0	9.7	9.7	9.7	9.7
Accounts payable	11.1	18.8	19.4	14.7	12.4	12.6	15.3
Other liabilities	9.7	9.4	10.9	3.2	3.2	3.2	3.2
Liabilities	75.2	98.6	124.0	116.6	114.3	114.5	117.2
Total liabilities and shareholders' equity	190.1	227.3	265.5	255.8	250.3	264.1	290.4

### **Financial Ratios**

	2020	2021	2022	2023	2024e	2025e	2026e
Efficiency of Capital Employment							
Operating Assets Turnover	3.0 x	2.7 x	2.7 x	2.2 x	2.5 x	3.2 x	3.8 x
Capital Employed Turnover	1.5 x	1.7 x	1.4 x	1.0 x	1.0 x	1.0 x	1.1 x
ROA	15.7 %	21.9 %	16.5 %	-10.3 %	-4.9 %	3.7 %	8.5 %
Return on Capital							
ROCE (NOPAT)	12.8 %	17.3 %	13.5 %	n.a.	n.a.	3.5 %	7.5 %
ROE	13.9 %	17.0 %	15.8 %	-9.8 %	-5.1 %	3.9 %	8.7 %
Adj. ROE	13.4 %	17.0 %	15.8 %	-9.8 %	-5.1 %	3.9 %	8.7 %
Balance sheet quality							
Net Debt	-1.7	1.2	52.4	58.5	52.2	43.5	36.8
Net Financial Debt	-2.8	-0.4	50.4	57.2	50.8	42.2	35.4
Net Gearing	-1.5 %	0.9 %	37.0 %	42.0 %	38.4 %	29.1 %	21.2 %
Net Fin. Debt / EBITDA	n.a.	n.a.	110.2 %	3366.5 %	581.9 %	152.3 %	86.6 %
Book Value / Share	3.7	4.3	4.7	4.5	4.4	4.9	5.6
Book value per share ex intangibles	1.6	2.1	1.6	1.6	1.1	1.0	1.1



# Book Value per Share in EUR



COMMENT

Published 08.11.2024 7

### Consolidated cash flow statement




In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Net income	15.1	20.8	21.4	-13.8	-7.0	5.6	14.1
Depreciation of fixed assets	6.3	6.3	5.5	7.3	7.2	7.8	8.5
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	8.2	9.8	11.3	16.3	10.0	10.6	11.2
Increase/decrease in long-term provisions	1.1	6.6	-1.3	-5.3	0.0	0.0	0.0
Other non-cash income and expenses	5.1	5.1	0.0	-8.4	0.0	0.0	0.0
Cash Flow before NWC change	35.9	48.6	36.9	-3.9	10.2	24.0	33.8
Increase / decrease in inventory	0.9	-17.1	-13.2	6.3	14.7	4.4	-4.4
Increase / decrease in accounts receivable	-0.1	-13.8	-7.9	13.8	5.0	0.4	-2.4
Increase / decrease in accounts payable	0.5	7.8	0.6	-4.5	-2.3	0.2	2.7
Increase / decrease in other working capital positions	0.1	-0.1	-4.0	-7.3	0.0	0.0	0.0
Increase / decrease in working capital (total)	1.5	-23.2	-24.5	8.2	17.5	5.0	-4.1
Net cash provided by operating activities [1]	37.3	25.3	12.4	4.2	27.7	29.0	29.7
Investments in intangible assets	-20.6	-11.8	-20.8	-11.6	-12.5	-14.9	-16.9
Investments in property, plant and equipment	-2.7	-3.9	-8.6	-1.9	-2.7	-3.4	-4.0
Payments for acquisitions	0.0	0.0	-14.5	0.0	-4.2	0.0	0.0
Financial investments	0.0	0.0	0.0	-0.4	0.0	0.0	0.0
Income from asset disposals	0.2	0.4	0.3	0.4	0.0	0.0	0.0
Net cash provided by investing activities [2]	-23.3	-15.3	-44.2	-13.4	-19.4	-18.3	-20.9
Change in financial liabilities	2.3	10.4	18.0	0.3	0.0	0.0	0.0
Dividends paid	-2.6	-5.8	-6.2	-4.2	0.0	0.0	0.0
Purchase of own shares	-0.2	-3.9	-2.7	17.7	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	-0.8	0.1	0.0	0.0	0.0	0.0	0.0
Net cash provided by financing activities [3]	-1.3	-3.1	5.7	12.7	-2.0	-2.0	-2.0
Change in liquid funds [1]+[2]+[3]	12.7	7.0	-26.1	3.5	6.3	8.7	6.8
Effects of exchange-rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	47.9	54.8	28.7	32.2	38.5	47.2	54.0

### **Financial Ratios**

	2020	2021	2022	2023	2024e	2025e	2026e
Cash Flow							
FCF	13.8	9.6	-17.6	-9.3	12.5	10.7	8.8
Free Cash Flow / Sales	8.1 %	4.5 %	-6.5 %	-4.6 %	6.9 %	5.6 %	3.9 %
Free Cash Flow Potential	24.9	29.8	31.3	3.0	5.8	19.2	28.2
Free Cash Flow / Net Profit	91.6 %	46.3 %	-82.3 %	67.2 %	-179.9 %	189.9 %	62.2 %
Interest Received / Avg. Cash	2.7 %	0.4 %	0.7 %	10.8 %	1.1 %	0.9 %	0.8 %
Interest Paid / Avg. Debt	1.6 %	1.2 %	1.6 %	2.1 %	2.1 %	2.1 %	2.1 %
Management of Funds							
Investment ratio	13.7 %	7.3 %	10.8 %	6.6 %	8.4 %	9.6 %	9.4 %
Maint. Capex / Sales	2.6 %	3.5 %	2.8 %	2.5 %	3.1 %	3.3 %	3.2 %
Capex / Dep	160.6 %	97.2 %	174.8 %	57.2 %	88.5 %	99.7 %	106.2 %
Avg. Working Capital / Sales	17.1 %	18.6 %	22.7 %	31.7 %	26.5 %	19.2 %	16.3 %
Trade Debtors / Trade Creditors	175.9 %	176.9 %	212.1 %	186.9 %	180.6 %	174.6 %	159.5 %
Inventory Turnover	4.1 x	2.8 x	2.8 x	2.7 x	3.1 x	3.8 x	3.8 x
Receivables collection period (days)	42	57	55	49	45	42	40
Payables payment period (days)	49	67	50	46	50	48	50
Cash conversion cycle (Days)	82	122	136	141	113	89	86

#### **CAPEX and Cash Flow** in EUR m




#### **Free Cash Flow Generation**

2021

2022

FCF (m) - Free Cash Flow / Sales

#### **Working Capital**



COMMENT

Published 08.11.2024

2023 2024e 2025e

2026e

8



#### LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

#### **COPYRIGHT NOTICE**

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

# DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <u>http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</u>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

#### SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



#### Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.

3. CIC (Crédit Industriel et Commercial) and M.M.Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.

4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.

5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

# Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a share of more than 5% of the equity capital of the analysed company.
- -2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- -4 MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide investment banking and/or investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analyse
---

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Basler	3, 5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005102008.htm



#### INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.	
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.	
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.	
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.	

#### WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	139	69
Hold	46	23
Sell	10	5
Rating suspended	6	3
Total	201	100

#### WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	40	73
Hold	11	20
Sell	2	4
Rating suspended	2	4
Total	55	100



PRICE AND RATING HISTORY BASLER AS OF 08.11.2024

Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode Head of Equities	+49 40 3282-2678 mrode@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research	+49 40 309537-280 mheider@warburg-research.com	Hannes Müller Software, IT	+49 40 309537-255 hmueller@warburg-research.com
Henner Rüschmeier Head of Research	+49 40 309537-270 hrueschmeier@warburg-research.com	Andreas Pläsier Banks, Financial Services	+49 40 309537-246 aplaesier@warburg-research.com
<b>Stefan Augustin</b> Cap. Goods, Engineering	+49 40 309537-168 saugustin@warburg-research.com	Malte Schaumann Technology	+49 40 309537-17( mschaumann@warburg-research.con
Jan Bauer Renewables	+49 40 309537-155 jbauer@warburg-research.com	Oliver Schwarz Chemicals, Agriculture	+49 40 309537-250 oschwarz@warburg-research.con
Christian Cohrs Industrials & Transportation	+49 40 309537-175 ccohrs@warburg-research.com	Simon Stippig Real Estate, Telco	+49 40 309537-265 sstippig@warburg-research.con
<b>Dr. Christian Ehmann</b> BioTech, Life Science	+49 40 309537-167 cehmann@warburg-research.com	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.con
Felix Ellmann Software, IT	+49 40 309537-120 fellmann@warburg-research.com	Robert-Jan van der Horst	+49 40 309537-290 rvanderhorst@warburg-research.com
Jörg Philipp Frey Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com	Andreas Wolf Software. IT	+49 40 309537-14( awolf@warburg-research.com
Marius Fuhrberg Financial Services	+49 40 309537-185 mfuhrberg@warburg-research.com	, , ,	
Fabio Hölscher Automobiles, Car Suppliers	+49 40 309537-240 fhoelscher@warburg-research.com		
Philipp Kaiser Real Estate, Construction	+49 40 309537-260 pkaiser@warburg-research.com		
Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257 tkleibauer@warburg-research.com		
INSTITUTIONAL EQUI	TY SALES		
Klaus Schilling	+49 69 5050-7400	Sascha Propp	+49 40 3282-2656
Head of Equity Sales, Germany	kschilling@mmwarburg.com	France	spropp@mmwarburg.com
Tim Beckmann United Kingdom	+49 40 3282-2665 tbeckmann@mmwarburg.com		
Jens Buchmüller	+49 69 5050-7415		
Scandinavia, Austria	jbuchmueller@mmwarburg.com		
Matthias Fritsch	+49 40 3282-2696	Leyan Ilkbahar	+49 40 3282-2695
United Kingdom, Ireland	mfritsch@mmwarburg.com	Roadshow/Marketing	lilkbahar@mmwarburg.com
Rudolf Alexander Michaelis		Antonia Möller Roadshow/Marketing	+49 69 5050-7417
Germany Roman Alexander Niklas	rmichaelis@mmwarburg.com +49 69 5050-7412	Juliane Niemann	amoeller@mmwarburg.com +49 40 3282-2694
Switzerland, Poland, Italy	rniklas@mmwarburg.com	Roadshow/Marketing	jniemann@mmwarburg.com
SALES TRADING		DESIGNATED SPONSOR	RING
Oliver Merckel	+49 40 3282-2634	Marcel Magiera	+49 40 3282-2662
Head of Sales Trading	omerckel@mmwarburg.com	Designated Sponsoring	mmagiera@mmwarburg.com
Rico Müller Sales Trading	+49 40 3282-2685 rmueller@mmwarburg.com	Sebastian Schulz Designated Sponsoring	+49 40 3282-2631 sschulz@mmwarburg.com
Bastian Quast	+49 40 3282-2701	Jörg Treptow	+49 40 3282-2658
Sales Trading	bquast@mmwarburg.com	Designated Sponsoring	jtreptow@mmwarburg.com
MACRO RESEARCH			
Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com
Our research can be fo	ound under:		
Warburg Research	research.mmwarburg.com/en/index.html	LSEG	www.lseg.com
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		
For access please conta	ct:		
Andrea Schaper	+49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703